Adam Savitz - 03 Jul 2025 Form 4 Insider Report for Alto Neuroscience, Inc. (ANRO)

Role: CHIEF MEDICAL OFFICER
Signature: /s/ Erin R. McQuade, Attorney-in-Fact
Issuer symbol: ANRO
Transactions as of: 03 Jul 2025
Net transactions value: $0
Form type: 4
Filing time: 08 Jul 2025, 17:22:02 UTC
Previous filing: 07 Feb 2025
Next filing: 13 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Savitz Adam	CHIEF MEDICAL OFFICER	C/O ALTO NEUROSCIENCE, INC., 650 CASTRO STREET, SUITE 450, MOUNTAIN VIEW	/s/ Erin R. McQuade, Attorney-in-Fact	08 Jul 2025	0002008707

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ANRO	Employee Stock Option (Right to Buy)	Award		+22,481			22,481	03 Jul 2025	Common Stock	22,481	$2.35	Direct	F1, F2, F3
transaction	ANRO	Employee Stock Option (Right to Buy)	Disposed to Issuer		-22,481	-100%		0	03 Jul 2025	Common Stock	22,481	$6.23	Direct	F1, F2, F3
transaction	ANRO	Employee Stock Option (Right to Buy)	Award		+33,008			33,008	03 Jul 2025	Common Stock	33,008	$2.35	Direct	F2, F3, F4
transaction	ANRO	Employee Stock Option (Right to Buy)	Disposed to Issuer		-33,008	-100%		0	03 Jul 2025	Common Stock	33,008	$6.23	Direct	F2, F3, F4
transaction	ANRO	Employee Stock Option (Right to Buy)	Award		+123,645			123,645	03 Jul 2025	Common Stock	123,645	$2.35	Direct	F2, F3, F5
transaction	ANRO	Employee Stock Option (Right to Buy)	Disposed to Issuer		-123,645	-100%		0	03 Jul 2025	Common Stock	123,645	$5.30	Direct	F2, F3, F5
transaction	ANRO	Employee Stock Option (Right to Buy)	Award		+73,000			73,000	03 Jul 2025	Common Stock	73,000	$2.35	Direct	F2, F3, F6
transaction	ANRO	Employee Stock Option (Right to Buy)	Disposed to Issuer		-73,000	-100%		0	03 Jul 2025	Common Stock	73,000	$14.88	Direct	F2, F3, F6
transaction	ANRO	Employee Stock Option (Right to Buy)	Award		+76,000			76,000	03 Jul 2025	Common Stock	76,000	$2.35	Direct	F2, F3, F7
transaction	ANRO	Employee Stock Option (Right to Buy)	Disposed to Issuer		-76,000	-100%		0	03 Jul 2025	Common Stock	76,000	$4.20	Direct	F2, F3, F7

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares subject to the option are fully vested and exercisable.
F2	The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on July 3, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices greater than $2.35 per share held by continuing employees of the Issuer as of the Repricing Date.
F3	Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $2.35 per share, the closing price of the Issuer's common stock on the Repricing Date. However, if an employee exercises a repriced option before the end of a retention period of one year (subject to earlier termination in certain circumstances), such employee will be required to pay the original exercise price per share of such repriced option. There is no change to the vesting schedules, expiration dates of, or number of shares underlying the repriced options.
F4	25% of the shares underlying the option vested on January 1, 2024, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.
F5	25% of the shares underlying the option vested on December 20, 2024, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.
F6	25% of the shares underlying the option vested on March 1, 2025, and one forty-eighth (1/48th) of the shares underlying the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.
F7	25% of the shares underlying the option shall vest on February 5, 2026, and one forty-eighth (1/48th) of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.